Participating Companies

Affibody
Lead can­di­date Izok­ibep, sup­port­ed by part­n­er­ship with Ace­lyrin, is an IL-17 in­hibi­tor with mul­ti­ple Ph2 pro­grams in progress (PSO, axS­pA, uvei­tis, HS, PsA). ACR50 pri­mary end­point met for 16 wk da­ta in PsA. First pa­tient dosed in piv­o­tal Phase 2b trial for uvei­tis filed in 1H2022 with 24 wk da­ta ex­pect­ed in 2023. On­go­ing re­la­tion­ship with In­ma­gene in Chi­na. [more in­for­ma­tion]
Affimed [AFMD] $114 MM MCap
On­col­o­gy ther­a­peu­tics de­vel­op­er with most ad­vanced AFM13 for r/r pe­ripher­al T-cell lym­pho­ma com­plet­ing Ph2 en­roll­ment. AFM24 for mul­ti­ple solid tu­mors is in Ph 2a as monother­a­py. [more in­for­ma­tion]
Agiliti Health [AGTI] $1,943 MM MCap
Agil­i­ti serves more than 9,000 na­tio­n­al, re­gio­n­al and lo­cal acute care and al­ter­nate site providers across the U.S. For more than eight de­cades, Agil­i­ti has de­liv­ered med­i­cal equip­ment ma­n­age­ment and ser­vice so­lu­tions that help health­care providers re­duce costs, in­crease op­er­at­ing ef­fi­cien­cies and sup­port op­ti­mal pa­tient out­comes. [more in­for­ma­tion]
Akili [AKLI] $95 MM MCap
Pre­scrip­tion dig­i­tal ther­a­peu­tics com­pany (PDT) with En­dea­v­or­Rx, the first FDA-cleared video game treat­ment op­tion for AD­HD (pe­di­a­tric pa­tients). The com­pany set com­mer­cial launch for En­dea­v­or­Rx for 2H 2022. Ak­ili has pro­ject­ed $500M in sales po­ten­tial for En­dea­v­or­Rx for the US AD­HD mar­ket achiev­able within 5-7 years post-launch. [more in­for­ma­tion]
Alladapt
De­vel­op­ing a po­ten­tial­ly best-in-class oral im­munother­a­py that ad­dress­es a broad range of food al­ler­gies. AD­P101, which is in a Ph 1/2 study and an OLE study, is de­signed to de­sen­si­tize pa­tients al­ler­g­ic to one or to mul­ti­ple foods si­mul­ta­ne­ous­ly to miti­gate the risk of se­vere, life-threat­en­ing al­ler­g­ic re­ac­tions. The Com­pany was co-found­ed by Dr. Kari Nadeau, a renowned food al­ler­gist, and former 23andMe ex­ec, Ash­ley Dom­bkows­ki who serves is CEO. Da­ta from Ph 1/2 study ex­pect­ed 1Q23. [more in­for­ma­tion]
Arbor Biotechnologies
As the Com­pany cont­in­ues to ad­vance its pipe­line to­ward the clin­ic with an ini­tial fo­cus in liv­er and CNS dis­ease, Ar­bor al­so se­cured sev­er­al part­n­er­ships around gene edit­ing and ex vi­vo cell ther­a­py pro­grams to broa­d­en the reach of its nov­el nu­clease tech­nol­o­gy. [more in­for­ma­tion]
Arbutus Biopharma [ABUS] $491 MM MCap
To ad­dress HBV, de­vel­op­ing a RNAi ther­a­peu­tic, an oral PD-L1 in­hibi­tor, and oral RNA desta­bi­l­iz­er and in­tend to com­bine with the aim of pro­vid­ing a func­tio­n­al cure for pa­tients with chron­ic HBV by sup­press­ing vi­ral re­pli­ca­tion, re­duc­ing sur­face anti­gen and reawak­en­ing the im­mune sys­tem. AB-729, is po­ten­tial­ly the on­ly RNAi ther­a­peu­tic with evi­dence of im­mune re-awak­en­ing. [more in­for­ma­tion]
AxoGen [AXGN] $380 MM MCap
Lead­ing com­pany fo­cused on de­vel­op­ment and com­mer­cial­iza­tion of tech­nolo­gies for pe­ripher­al nerve re­gen­er­a­tion and re­pair. Lead prod­uct Avance Nerve graft is bi­o­log­i­cal­ly-ac­tive OTS hu­man al­lo­graft. FY 2022 rev­enue gui­dance of $135-$142M rep­re­sents 10%-15% YOY growth ex. $4.1M from dis­cont­in­ued Avive rev­enue. [more in­for­ma­tion]
Bavarian Nordic A/S [BAVA]
Glob­al lead­er in vaccines for in­fec­tious dis­eas­es. Com­mer­cial prod­ucts in­clude the world’s on­ly ap­proved mon­key­pox vaccine and mar­ket-lead­ing vaccines against ra­bies, tick-borne en­cephali­tis, in ad­di­tion to an Ebo­la vaccine li­censed to Janssen. Com­pany de­liv­ered more than 4 mil­lion dos­es of mon­key­pox vaccines in 2022 cov­er­ing more than 70 coun­tries and ex­pects to sup­p­ly ~10 mil­lion dos­es through 2023. En­roll­ment is on­go­ing in glob­al Ph 3 COVID boost­er trial and glob­al Ph 3 RSV trial with ac­cess to ac­cel­er­at [more in­for­ma­tion]
BenevolentAI [BAI]
Com­bines ad­vanced AI and ma­chine learn­ing with cutt­ing edge sci­ence to de­ci­pher com­plex dis­ease bi­ol­o­gy, gen­er­ate nov­el in­sights and dis­cov­er more ef­fec­tive medicines. The unique com­pu­ta­tio­n­al R&D plat­form spans ev­ery step of the drug dis­cov­ery pro­cess, pow­er­ing a grow­ing in-house pipe­line of 13 named drug pro­grammes and over 10 ex­plo­ra­to­ry pro­grammes, main­tain­ing suc­cess­ful col­lab­o­ra­tions. [more in­for­ma­tion]
Benitec Biopharma [BNTC] $6 MM MCap
A na­t­u­ral his­to­ry study to col­lect base­line da­ta in OP­MD pa­tients ne­ces­sary for a clin­i­cal trial is ex­pect­ed to be­gin 4Q22, with the clin­i­cal study to fol­low. [more in­for­ma­tion]
Bexion Pharmaceuticals
A clin­i­cal-stage bio­phar­ma­ceu­ti­cal com­pany de­vel­op­ing a new gen­er­a­tion of bi­o­log­ic im­munother­a­py to treat Solid Tu­mor Can­cers and Che­mother­a­py In­duced Pe­ripher­al Neu­ro­pa­thy (CIPN). Bexion's lead as­set BXQ-350 ac­ti­vates Sphin­goloid Metabolism and has de­mon­s­trat­ed ex­cel­lent safe­ty and monother­a­py ben­e­fits across mul­ti­ple tu­mor types in its com­plet­ed adult and pe­di­a­tric Ph 1 study. Ph 2 study in CRC ex­pect­ed 4Q22. The Com­pany has $80M raised to date. [more in­for­ma­tion]
CellMax Life
Pri­vate liquid biop­sy com­pany ded­i­cat­ed to trans­form­ing how can­cer is de­tect­ed and ma­n­aged with glob­al­ly af­ford­able non-in­va­sive blood tests for ear­ly can­cer de­tec­tion and mon­i­tor­ing. The com­pany is cur­rent­ly fo­cused on col­orec­tal can­cer (CRC) screen­ing us­ing the clin­i­cal­ly vali­dat­ed First­Sight (TM), a blood biop­sy test that de­tects pre-can­cer­ous le­sions (ade­no­mas) in as lit­tle as two tea­spoons of blood (less than 10mL). First­Sight is mar­ket­ed for reg­u­lar test­ing in pa­tients 45 years and old­er. [more in­for­ma­tion]
Compass Pathways [CMPS] $356 MM MCap
Men­tal health com­pany fo­cused on psilo­cy­bin ther­a­py in con­junc­tion with psy­cho­log­i­cal sup­port, with FDA Break­through Ther­a­py desig­na­tion for lead as­set COM­P360 in treat­ment-re­sis­tant de­pres­sion. Top-line Ph 2b da­ta showed sig­ni­f­i­cant im­prove­ments in de­pres­sive symp­toms, Ph 3 to com­mence in Q4 '22. Add'l Ph 2 trials in PTSD and anorexia ner­vosa on­go­ing. [more in­for­ma­tion]
Corium
Com­mer­cial-stage neu­ro­s­cience com­pany lead­ing de­vel­op­ment and com­mer­cial­iza­tion of neu­ro­s­cience ther­a­pies. Two FDA-ap­proved drugs AZS­TARYS (AD­HD) and AD­LAR­I­TY (Alzheimer's Dis­ease) rep­re­sent com­bined peak sales po­ten­tial in ex­cess of >$1B. [more in­for­ma­tion]
CureVac [CVAC] $1,523 MM MCap
Based on its pro­pri­e­tary tech­nol­o­gy, Cure­Vac has built a deep clin­i­cal pipe­line across the ar­eas of pro­phy­lac­tic vaccines, can­cer ther­a­pies, anti­body ther­a­pies, and the treat­ment of rare dis­eas­es. [more in­for­ma­tion]
Delcath Systems, Inc. [DCTH] $46 MM MCap
In­ter­ven­tio­n­al on­col­o­gy com­pany fo­cused on the treat­ment of pri­mary and me­tastat­ic liv­er can­cers. Com­pany’s pro­pri­e­tary per­cu­ta­neous he­p­at­ic per­fu­sion (PHP) sys­tem is de­signed to ad­min­is­ter high-dose che­mother­a­py to the liv­er while con­trolling sys­temic ex­po­sure and as­so­ci­at­ed side ef­fects. In the U.S., the PHP sys­tem is be­ing de­vel­oped un­der the tra­de­name HEP­ZA­TO KIT or HEP­ZA­TO, and is con­sid­ered a com­bi­na­tion drug and de­vice prod­uct reg­u­lat­ed by the FDA. [more in­for­ma­tion]
DURECT [DRRX] $114 MM MCap
Lead com­pound, lar­su­cos­terol, grant­ed FDA Fast Track Desig­na­tion for al­co­hol-as­so­ci­at­ed he­p­ati­tis (AH), re­sult­ed in 100% 28-day sur­vi­val for AH pa­tients in a Phase IIa study, with Phase IIb trial en­roll­ment com­ple­tion an­ti­ci­pat­ed 2Q23. [more in­for­ma­tion]
ESSA Pharma [EPIX] $87 MM MCap
De­vel­op­ing nov­el ther­a­pies for the treat­ment of pros­tate can­cer tar­get­ing the N-ter­mi­nal do­main of the an­dro­gen re­cep­tor. ES­SA’s lead clin­i­cal can­di­date, EPI-7386 is a high­ly-se­lec­tive, oral, small molecule in­hibi­tor of the N-ter­mi­nal do­main of the an­dro­gen re­cep­tor in de­vel­op­ment as a monother­a­py (Ph 1) and in com­bi­na­tion with stan­dard-of-care an­tian­dro­gens in pa­tients with cas­tra­tion-re­sis­tant pros­tate can­cer (Ph 1/2). [more in­for­ma­tion]
Galera [GRTX] $91 MM MCap
Clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pany trans­form­ing ra­dio­ther­a­py in can­cer. Lead as­set ava­so­pasem is a po­tent, high­ly se­lec­tive small molecule dis­mu­tase mimet­ic be­ing de­vel­oped for se­vere oral mu­cosi­tis (SOM). To­p­line Ph 3 da­ta an­nounced in 4Q21, with NDA sub­mis­sion ex­pect­ed by the end of 2022. Com­ple­tion of en­roll­ment for se­cond as­set ru­cos­a­pasem in two an­ti-can­cer studies is ex­pect­ed 2H23. [more in­for­ma­tion]
GENFIT [GNFT] $202 MM MCap
De­vel­op­ment pro­grams ad­dress­ing rare and se­vere liv­er dis­eas­es. Ph3 da­ta for ela­fi­branor in pri­mary biliary cholan­gi­tis (PBC) EL­A­TIVE study, ex­pect­ed 2Q23. Ac­qui­si­tion of Ver­san­tis brings VS-01-ACLF, a Ph2 ready pro­gram for se­vere liv­er dis­ease. Li­cens­ing and de­vel­op­ment agree­ment with IPSEN be­gan De­cem­ber 2021. [more in­for­ma­tion]
Geron [GERN] $1,190 MM MCap
Late-stage bio­phar­ma­ceu­ti­cal com­pany pur­su­ing ther­a­pies for pa­tients with he­ma­to­log­ic ma­lig­nan­cies. First-in-class telom­erase in­hibi­tor, ime­tel­s­tat, in two Ph3 piv­o­tal clin­i­cal trials in low­er risk myelodys­plas­tic syn­dromes (LR MDS; top-line da­ta ear­ly Jan 2023), and in re­lapsed/re­frac­to­ry myelo­fi­bro­sis (MF). [more in­for­ma­tion]
HUTCHMED [HCM] $2,504 MM MCap
NAS­DAQ, AIM and Hong Kong-list­ed glob­al com­mer­cial-stage on­col­o­gy com­pany with 3 ap­proved and mar­ket­ed tar­get­ed can­cer drugs in Chi­na and plans for reg­u­la­to­ry sub­mis­sions in the US, EU and Ja­pan in 2023. Key part­n­er­ships with Eli Lil­ly, As­traZene­ca and Bei­Gene. [more in­for­ma­tion]
ImmuneSensor
A pri­vate, clin­i­cal stage ther­a­peu­tic in­nate im­mu­ni­ty com­pany de­vel­op­ing drugs tar­get­ing the cGAS-ST­ING path­way for the treat­ment of can­cer and au­toim­mune dis­eas­es. The com­pany was co-found­ed by Dr. Zhi­jian “James” Chen of UTSW who won the 2019 Break-through prize and 2018 Lurie prize for the dis­cov­ery of the cGAS-ST­ING path­way. The com­pany pipe­line in­cludes a clin­i­cal stage ST­ING ag­on­ist, cur­rent­ly in monother­a­py and ICI com­bi­na­tion trial, with ex­pec­ta­tions to en­ter Phase 2 in 2H23. [more in­for­ma­tion]
Immunocore [IMCR] $2,445 MM MCap
A pi­oneer­ing, com­mer­cial-stage T cell re­cep­tor biotech­nol­o­gy com­pany work­ing to de­vel­op and com­mer­cial­ize a new gen­er­a­tion of trans­for­ma­tive medicines to ad­dress un­met needs in can­cer, in­fec­tion and au­toim­mune dis­ease, with the first TCR ther­a­peu­tic to re­ceive reg­u­la­to­ry ap­pro­val. [more in­for­ma­tion]
KBio
Cre­at­ing the new gen­er­a­tion of bi­o­log­ics us­ing its plant-based plat­form that has de­mon­s­trat­ed an abil­i­ty to cre­ate po­ten­tial­ly bet­ter drug can­di­dates at a frac­tion of the time and cost of con­ven­tio­n­al plat­forms. Fo­cused on dis­cov­er­ing mon­o­clo­n­al anti­bodies tar­get­ing vali­dat­ed path­ways for rare and in­fec­tious dis­eas­es and, due to the speed and ac­cu­ra­cy of its anti­body pro­duc­tion sys­tem, is po­si­tioned well to de­vel­op fast fol­low­er ther­a­pies against vali­dat­ed drug tar­gets. [more in­for­ma­tion]
Keros Therapeutics [KROS] $1,257 MM MCap
A lead­er in un­der­s­tand­ing the role of the TGF-Be­ta fam­i­ly of pro­teins that is a mas­ter reg­u­la­tor of RBC and platelet pro­duc­tion as well as the growth, re­pair and main­te­nance of mus­cle and bone. Lead pro­tein ther­a­peu­tic prod­uct can­di­date, KER-050, be­ing de­vel­oped for the treat­ment of cy­tope­nias, in­clud­ing ane­mia and throm­bo­cy­tope­nia, in pa­tients with MDS and MF. KER-012 is be­ing de­vel­oped for the treat­ment of PAH and for the treat­ment of di­s­or­ders as­so­ci­at­ed with bone loss. [more in­for­ma­tion]
Kezar Life Sciences [KZR] $259 MM MCap
Clin­i­cal stage biotech­nol­o­gy com­pany pi­oneer­ing first-in-class, small molecule ther­a­pies by tar­get­ing key in­tra­cel­lu­lar pro­teins. Lead can­di­date, ze­tomip­zomib (KZR-616), a se­lec­tive im­muno­pro­tea­some in­hibi­tor, is be­ing eval­u­at­ed in Phase 2 clin­i­cal trials for lu­pus nephri­tis and au­toim­mune he­p­ati­tis, and KZR-261, a first-in-class in­hibi­tor of the Sec61 trans­lo­con de­vel­oped us­ing the Com­pany’s nov­el Plat­form, is un­der­go­ing a Phase 1 clin­i­cal trial for the treat­ment of ad­vanced/me­tastat­ic solid tu­mors. [more in­for­ma­tion]
Longboard Pharmaceuticals [LBPH] $100 MM MCap
Long­board is eval­u­at­ing LP352, an oral, cen­tral­ly act­ing 5-hy­drox­ytryp­tamine 2C (5-HT2C) re­cep­tor su­per­a­g­on­ist, with neg­li­gi­ble ob­served im­pact on 5-HT2B and 5-HT2A re­cep­tor sub­types, in de­vel­op­ment for the po­ten­tial treat­ment of seizures as­so­ci­at­ed with a broad range of de­vel­op­men­tal and epilep­tic en­cephalo­pathies. The com­pany is al­so eval­u­at­ing LP659, a cen­tral­ly act­ing, sphin­go­sine-1-phos­phate (S1P) re­cep­tor sub­types 1 and 5 mo­d­u­la­tor and LP143, a cen­tral­ly act­ing, full cann­abi­noid type 2 re­cep­tor (CB2). [more in­for­ma­tion]
Marker Therapeutics [MRKR] $16 MM MCap
Fo­cused on de­vel­op­ing next-gen­er­a­tion T cell-based im­munother­a­pies for the treat­ment of he­ma­to­log­i­cal ma­lig­nan­cies and solid tu­mor in­di­ca­tions. Mark­er's cell ther­a­py tech­nol­o­gy is based on the se­lec­tive ex­pan­sion of non-en­gi­neered, tu­mor-spe­cif­ic T cells that rec­og­nize tu­mor as­so­ci­at­ed anti­gens and kill tu­mor cells ex­press­ing those tar­gets. [more in­for­ma­tion]
MiNA Therapeutics
Lead­er in RNA ac­ti­va­tion (RNAa). Tech­nol­o­gy ca­pa­ble of drug­ging any pro­tein tar­get to in­crease na­t­u­ral pro­tein pro­duc­tion in pa­tients own cells. Im­muno-on­col­o­gy and rare dis­ease pipe­line with 10 clin­i­cal as­sets ex­pect­ed by 2025 and first FDA ap­pro­val in 2024. Key pro­grams in­clude MTL-CEP­BA (on­go­ing ran­domized Ph2 in 2L HCC, Ph1/1b in ad­vanced solid tu­mors re­sis­tant to an­ti-PD1), MTL-ST­ING, mono­gene­ic rare dis­ease pro­grams. $1.5B+ phar­ma part­n­er­ships. [more in­for­ma­tion]
Minerva Biotechnologies
A clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pany de­vel­op­ing can­cer im­munother­a­pies and drugs to tar­get 75% of solid tu­mors and to pre­vent can­cer me­tas­ta­sis. Min­er­va has a pipe­line that in­cludes next-gen CAR Ts and other mo­dal­i­ties. The Com­pany has an on­go­ing Phase I/II study of huM­NC2-CAR44, an au­tol­o­gous CAR T ther­a­py, tar­get­ing the tu­mor-as­so­ci­at­ed form of MUC1 (MUC1*) which is a growth fac­tor re­cep­tor that drives growth of an es­ti­mat­ed 93% of breast can­cers. [more in­for­ma­tion]
Monte Rosa Therapeutics [GLUE] $335 MM MCap
Mul­ti-as­set next-gen AI-driv­en molec­u­lar glue-based TPD plat­form. Lead pro­gram in Ph 1 fo­cused on GSP­T1, a key reg­u­la­tor and vul­n­er­a­bil­i­ty of MYC-driv­en solid tu­mors, in­clud­ing lung can­cer. [more in­for­ma­tion]
NexImmune [NEXI] $11 MM MCap
De­vel­op­ing unique ap­proach­es to T cell im­munother­a­pies based on its pro­pri­e­tary, mul­ti-anti­gen Ar­ti­fi­cial Im­mune Mo­d­u­la­tion (AIM™) tech­nol­o­gy. AIM™ tech­nol­o­gy em­ploys na­t­u­ral bi­ol­o­gy to di­rect spe­cif­ic T cell-me­di­at­ed im­mune re­spons­es ca­pa­ble of treat­ing a va­ri­e­ty of can­cers and au­toim­mune dis­eas­es. On­go­ing Phase I/II in R/R AML with da­ta ex­pect­ed around YE22. Ini­ti­at­ing a Phase I/II in HPV-me­di­at­ed solid tu­mors. Au­toim­mune pro­grams ad­vanc­ing quick­ly. [more in­for­ma­tion]
NorthSea Therapeutics
Fo­cused on de­vel­op­ing SE­FAs for the treat­ment of NASH and other metabolic di­s­or­ders. Phase 2b ICO­NA NASH trial icos­abu­tate showed sig­ni­f­i­cant de­creas­es in NASH and fi­brot­ic bio­mark­ers and is sche­d­uled to read­out biop­sy da­ta in 1Q23. Two ad­di­tio­n­al SE­FAs (1024 and 6179) in Phase 1 clin­i­cal trials for pa­tients with dys­lipi­demia and the or­phan in­di­ca­tion IFALD, re­spec­tive­ly. [more in­for­ma­tion]
Nykode Therapeutics [NYKD]
Clin­i­cal stage im­munother­a­py com­pany fo­cused on can­cer and in­fec­tious dis­ease. Mo­d­u­lar vaccine tech­nol­o­gy tar­gets anti­gens to Anti­gen Pre­sent­ing Cells to achieve rapid, strong and long-last­ing im­mune re­spons­es. Key pro­grams in­clude Ph2 pro­pri­e­tary HPV 16+ cer­vi­cal can­cer ther­a­peu­tic vaccine, Ph1/2 in­di­vi­d­u­al­ized can­cer neoanti­gen vaccine (Ge­nen­tech), Ph1/2 next-gen­er­a­tion COVID-19 T-cell vaccines. Sig­ni­f­i­cant col­lab­o­ra­tions with Re­generon, Ge­nen­tech, Adap­tive Biotech­nolo­gies. [more in­for­ma­tion]
Pharming Group [PHAR] $668 MM MCap
Build­ing a sus­tain­able rare dis­ease busi­ness, pre­par­ing for ap­pro­val/launch of le­ni­olis­ib for APDS. Rev­enues >$200M (TTM) from Ru­con­est (mar­ket­ed) for the treat­ment of acute hered­i­tary an­gioede­ma (HAE) at­tacks in­clud­ing break­through at­tacks. Le­ni­olis­ib, a tar­get­ed PI3K&del­ta; in­hibi­tor ini­tial­ly be­ing de­vel­oped for PI3K del­ta syn­drome (APDS), is on track to be the first ap­proved dis­ease-mod­i­fy­ing treat­ment for APDS, a rare ge­net­ic im­mun­od­e­fi­cien­cy, in Q1 2023 (FDA) and H1 2023 (EMA). Du­al list­ed on Nas­daq. [more in­for­ma­tion]
Photocure [PHCUF] $214 MM MCap
Lead prod­uct Hexvix®/Cysview® im­proves de­tec­tion of blad­der can­cer un­der blue light cys­tos­copy (BLC). Ap­proved in over 30 coun­tries, Hexvix®/Cysview® is di­rect­ly sold in the US and EU, and through world­wide part­n­er­ships. Pho­to­cure ex­pects up to $250M from li­cense of non-core as­set CE­VI­RA® to Asieris. Head­quar­tered in Os­lo, Nor­way, Pho­to­cure is 20% owned by US in­ves­tors (sig­ni­f­i­cant in­crease over past few years) and com­mer­cial­ly fo­cused on US mar­ket. [more in­for­ma­tion]
Pieris Pharmaceuticals [PIRS] $97 MM MCap
Lead pro­gram (AZN-part­nered) PRS-060, is an in­haled IL4Ra in­hibi­tor for mod­er­ate-to-se­vere asth­ma, with Phase 2 to­p­line da­ta ex­pect­ed by 3Q23; Phase 1/2 en­roll­ment cont­in­ues for Servi­er-part­nered PRS-344 (4-1BB/PD-L1 bis­pe­cif­ic) for solid tu­mors. [more in­for­ma­tion]
Redx Pharma [REDX]
Lead fi­bro­sis as­set, the se­lec­tive ROCK2 in­hibi­tor RX­C007, is in de­vel­op­ment for lung fi­bro­sis, with Ph2a to­p­line da­ta for idio­path­ic pul­mo­nary fi­bro­sis ex­pect­ed H223. Lead on­col­o­gy as­set, Por­cu­pine in­hibi­tor RX­C004, for Wnt de­pen­dent can­cers, Ph2 to­p­line da­ta ex­pect­ed start­ing in H123 and in­to H223. [more in­for­ma­tion]
Sonnet Biotherapeutics [SONN] $12 MM MCap
Clin­i­cal-stage mul­ti-as­set im­muno-on­col­o­gy ther­a­peu­tics plat­form com­pany fea­tur­ing pro­pri­e­tary tech­nol­o­gy im­prov­ing in vi­vo half-life and tu­mor tis­sue spe­ci­fic­i­ty of in­ter­leukins. SON-1010 (IL-12-FHAB) in phase I SAD and SON-080 (low dose IL-6) in phase 1b/2a. [more in­for­ma­tion]
Spruce Biosciences [SPRB] $92 MM MCap
Fo­cused on de­vel­op­ing and com­mer­cial­iz­ing nov­el ther­a­pies for rare en­docrine di­s­or­ders. The com­pany’s lead prod­uct can­di­date, Til­dac­er­font, is cur­rent­ly be­ing eval­u­at­ed for the treat­ment of clas­sic adult con­geni­tal adre­nal hy­per­pla­sia (CAH), and in up­com­ing studies in pe­di­a­tric clas­sic CAH and Po­ly­cys­tic Ovary Syn­drome (PCOS). [more in­for­ma­tion]
Sutro Biopharma [STRO] $286 MM MCap
Clin­i­cal-stage on­col­o­gy com­pany pi­oneer­ing site-spe­cif­ic and nov­el-for­mat anti­body drug con­ju­gates (ADCs). Sutro has two whol­ly owned ADCs in the clin­ic—STRO-002, a fo­late re­cep­tor al­pha (FolR&al­pha;)-tar­get­ing ADC, in clin­i­cal studies for ovarian and en­dome­trial can­cers; and STRO-001, a CD74-tar­get­ing ADC, in clin­i­cal studies for B-cell ma­lig­nan­cies. STRO-003, an op­ti­mal­ly de­signed ROR1-tar­get­ing ADC, is an­ti­ci­pat­ed to be the next pro­pri­e­tary prod­uct can­di­date to move in­to clin­i­cal studies. [more in­for­ma­tion]
Treos Bio
De­vel­ops pre­ci­sion pep­tide can­cer im­munother­a­pies us­ing pa­tient HLA tar­get recog­ni­tion ge­net­ics based on pro­pri­e­tary com­pu­ta­tio­n­al da­ta sci­ence. Tre­os’ lead can­di­date is Po­lyPEPI-1018, an off-the-shelf im­munother­a­py for the treat­ment of me­tastat­ic col­orec­tal can­cer cur­rent­ly in a bio­mark­er-based Phase 1b clin­i­cal trial. Tre­os has raised $42 mil­lion to date. [more in­for­ma­tion]
XWPharma
Fo­cused on pro­vid­ing po­ten­tial first- and best-in-class medicines for pa­tients suf­fer­ing from de­bil­i­tat­ing neu­ro­log­i­cal dis­eas­es. XW10172 is a clin­i­cal-stage con­ju­gate of the GABAB ag­on­ist, oxy­bate, in de­vel­op­ment as an in­vesti­ga­tio­n­al once-night­ly ther­a­py in­tend­ed to reg­u­late the pa­tient’s sleep cy­cle in Parkin­son's dis­ease and nar­colep­sy. XW10508 is a glu­ta­mater­g­ic NM­DA an­ta­g­on­ist and AM­PA ac­ti­va­tor in de­vel­op­ment as an oral, once-dai­ly ther­a­py for ma­jor de­pres­sive di­s­or­der and chron­ic pain. [more in­for­ma­tion]
Zentalis [ZNTL] $1,092 MM MCap
De­vel­op­ing best-in-class small molecule ther­a­peu­tics tar­get­ing fun­da­men­tal bi­o­log­i­cal can­cer path­ways. Lead can­di­dates are ZN-c3, a Wee1 in­hibi­tor for ad­vanced solid tu­mors and ZN-d5, a BCL-2 in­hibi­tor for he­ma­to­log­ic ma­lig­nan­cies and re­lat­ed di­s­or­ders. Mul­ti­ple mono and com­bo trials are on­go­ing/planned across the pipe­line. [more in­for­ma­tion]